Compare Bristol-Myers Squibb Co (BMY) vs Quantum Computing Inc (QUBT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Quantum Computing Inc — how do they compare? Bristol-Myers Squibb Co trades at $63.67 (market cap $129.94B), while Quantum Computing Inc trades at $8.89 (market cap $2.03B). The key difference: Bristol-Myers Squibb Co is far larger — about 64× Quantum Computing Inc's market cap, and Bristol-Myers Squibb Co pays a 3.96% dividend while Quantum Computing Inc pays none. Which is the better fit depends on your goals.
| BMY | QUBT | |
|---|---|---|
Market Cap | $129.94B | $2.03B |
Sector | Health | Technology |
52-Week High | $65.89 | $24.62 |
52-Week Low | $42.60 | $6.31 |
Enterprise Value | $163.92B | $1.09B |
Dividend Yield | 3.96% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $63.88, down 1.48% on the day, with strong technical momentum indicated by bullish moving averages and ADX signals. The company demonstrates robust fundamentals with a 14.01 P/E ratio, 18.87% net income margin, and consistent earnings beats in recent quarters. Recent developments include a $2.3 billion manufacturing investment in Houston and strategic AI collaboration with Schrödinger.
BMY presents a compelling investment case with attractive valuation metrics and strong profitability, though investors face risks from patent expirations and debt levels. Analyst consensus suggests 7% upside to the $68.56 price target, with the stock offering dividend income alongside growth potential from pipeline developments and potential M&A activity.
Quantum Computing Inc. (QUBT) trades at $8.92, down slightly by 0.11% on the day, with a bearish technical signal. The company is in a high-growth but pre-profit phase, reporting Q2 2026 revenue of $5.6 million (MarketBeat, 2026-08-10), a significant increase, but with persistent net losses. Analyst sentiment is positive with a 75% buy rating and a consensus price target of $18.50, indicating substantial upside potential from current levels.
The outlook for QUBT is speculative, offering high growth potential in quantum computing and photonics, supported by strong institutional interest and revenue expansion. Key risks include steep valuation (P/S of 189.05), ongoing losses, high cash burn, and competitive pressures in the emerging quantum sector, requiring careful risk assessment by investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Quantum Computing Inc
Quantum Computing Inc. is a company focused on providing accessible quantum computing and quantum-enhanced software solutions for complex problems. The company's technology is designed to run on both classical and quantum hardware, enabling businesses to explore the power of quantum computing today for applications in finance, drug discovery, and logistics. QUBT offers a platform that makes quantum algorithms and software available through the cloud, aiming to democratize access to this advanced computing paradigm.
Read more on QUBT →
